FCN-159
Phase 2Small molecule
FCN-159 is one of 59 small molecule programs targeting Neurofibromatosis Type 1. It is currently in Phase 2.
4
Indications
4
Total Trials
4
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Phase II
#DrugCompanyPhaseTrials
1Xtandi
AstellasPhase 3
Rituxan
RochePhase 2
Lynparza
AstraZenecaPhase 2
LUNSUMIO
RochePhase 2
Herceptin
RochePhase 2
Imfinzi
AstraZenecaPhase 2
Adriamycin
PfizerPhase 2
Polivy
RochePhase 2
Tyrosine Kinase Inhibitor
PfizerPhase 3
SKB264
SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pediatric Patients1 trial
Venous malformation1 trial
Phase II1 trial
Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors
Recruiting·—·Phase 2·NCT06553365·30 enrolled
Neurofibromatosis Type 11 trial
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Active, not recruiting·SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 1/2·NCT04954001·160 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FCN-159. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details